Acute phase proteins (APPs) are primarily synthesized by the liver in response to various inflammatory signals, and serve as biomarkers of immune system perturbations. In response to inflammation, within a few hours the expression of the positive acute phase proteins like C -reactive protein, alpha2-macroglobulin, alpha1- antitrypsin, alpha1- acid glycoprotein, ceruloplasmin, haptoglobin, alpha1- antichymotrypsin, and serum amyloid A increases whereas the expression of transthyretin, retinol binding protein, cortisol binding globulin, transferrin and albumin, which represent the group of negative APPs, decreases. These changes in the production of APPs is controlled by a variety of cytokines released during inflammation but leading regulators are IL-1- and IL- 6 -type cytokines having additive, inhibitory, or synergistic effects. No doubt, these changes in expression of APPs represent a part of the organism’ s defense strategy to maintain homeostasis and tissue repair. Studies on the role of APPs as diagnostic and prognostic markers of infectious, inflammatory, and neoplastic diseases are expanding. By the present research topic, we aim to expand further our knowledge on the structure-functional relationship of APPs and their biological roles in different chronic and acute inflammatory conditions.
Acute phase proteins (APPs) are highly conserved proteins, which are secreted by the liver in response to a variety of injuries. Various extrahepatic tissues also express APPs. Therefore, hepatic and extrahepatic APPs can be found in the circulation. The selective alterations in APPs levels and molecular forms might serve as specific acute and chronic inflammatory indicators of the disease initiation, progression, and responses to therapies. Our goal is to improve the understanding of biological activities and co-interactions of specific APPs during health and pathological conditions. New insights on APPs may contribute to the development of novel therapies preventing systemic inflammation caused by all kinds of traumatizing insults.
We encourage authors to contribute with original research articles as well as with reviews. We would like to invite experimental and clinical contributions on APPs as biomarkers and immunomodulatory proteins reflecting health status or a broad spectrum of clinical and subclinical diseases, including cystic fibrosis, chronic obstructive lung diseases, rheumatoid arthritis, inflammatory bowel diseases, dementias, diabetes, skin diseases, cardiovascular disease, and cancer. We would like to focus on the structure-function relationship of specific APPs and their interactions with microenvironment.
Note on authors: Topic Editor Mari Dezawa received financial support from Life Science Institute, Inc. Topic Editor Joanna Chorostowska-Wynimko received financial support from Grifols, CSL Behring, AstraZeneca, Pfizer, MSD, BMS, Amgen, CelonPharma and Takeda. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Acute phase proteins (APPs) are primarily synthesized by the liver in response to various inflammatory signals, and serve as biomarkers of immune system perturbations. In response to inflammation, within a few hours the expression of the positive acute phase proteins like C -reactive protein, alpha2-macroglobulin, alpha1- antitrypsin, alpha1- acid glycoprotein, ceruloplasmin, haptoglobin, alpha1- antichymotrypsin, and serum amyloid A increases whereas the expression of transthyretin, retinol binding protein, cortisol binding globulin, transferrin and albumin, which represent the group of negative APPs, decreases. These changes in the production of APPs is controlled by a variety of cytokines released during inflammation but leading regulators are IL-1- and IL- 6 -type cytokines having additive, inhibitory, or synergistic effects. No doubt, these changes in expression of APPs represent a part of the organism’ s defense strategy to maintain homeostasis and tissue repair. Studies on the role of APPs as diagnostic and prognostic markers of infectious, inflammatory, and neoplastic diseases are expanding. By the present research topic, we aim to expand further our knowledge on the structure-functional relationship of APPs and their biological roles in different chronic and acute inflammatory conditions.
Acute phase proteins (APPs) are highly conserved proteins, which are secreted by the liver in response to a variety of injuries. Various extrahepatic tissues also express APPs. Therefore, hepatic and extrahepatic APPs can be found in the circulation. The selective alterations in APPs levels and molecular forms might serve as specific acute and chronic inflammatory indicators of the disease initiation, progression, and responses to therapies. Our goal is to improve the understanding of biological activities and co-interactions of specific APPs during health and pathological conditions. New insights on APPs may contribute to the development of novel therapies preventing systemic inflammation caused by all kinds of traumatizing insults.
We encourage authors to contribute with original research articles as well as with reviews. We would like to invite experimental and clinical contributions on APPs as biomarkers and immunomodulatory proteins reflecting health status or a broad spectrum of clinical and subclinical diseases, including cystic fibrosis, chronic obstructive lung diseases, rheumatoid arthritis, inflammatory bowel diseases, dementias, diabetes, skin diseases, cardiovascular disease, and cancer. We would like to focus on the structure-function relationship of specific APPs and their interactions with microenvironment.
Note on authors: Topic Editor Mari Dezawa received financial support from Life Science Institute, Inc. Topic Editor Joanna Chorostowska-Wynimko received financial support from Grifols, CSL Behring, AstraZeneca, Pfizer, MSD, BMS, Amgen, CelonPharma and Takeda. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
